BIOSAFETY DATABASES

Patents
Therapeutic Protein Production
GENETICALLY MODIFIED PLANTS COMPRISING SARS-CoV VIRAL NUCLEOTIDE SEQUENCES AND METHODS OF USE THEREOF FOR IMMUNIZATION AGAINST SARS, M Chye, H Li, R Sathishkumar, L L Poon & S M J Peiris (2005). University of Hing Kong, China. Patent # WO2005054473.
The invention relates to genetically modified plants and progeny thereof which constitute edible plant-derived mucosal vaccines and injectable plant-derived mucosal vaccines against Severe Acute Respiratory Syndrome (SARS). The invention relates to a recombinant vector that transforms specifically, but not limited to, the nuclei and/or plastids of tobacco, tomato and lettuce plants for antigen production. In specific embodiments, the plastid transformation vector expressing the nucleotide sequences are pCV1, pCV6 and pCV8, and their derivatives containing an S1 with nucleotide (but not amino acid) changes to optimize codon usage for expression in plants. The present invention relates to methods of making the modified plants which comprises transformation of plants with vectors for nuclear expression and/or plastid expression of nucleotide sequences of the SARS-CoV virus, fragments, derivatives, analogs, or variants thereof. The present invention also relates to methods of immunization against SARS and methods of antibody detection using the SARS-CoV antigens generated by the plastid and/or nuclear vector(s) transformed plants.
EXPRESSION OF THE HUMAN IGF-1 IN TRANSGENIC PLASTIDS, H Daniell (2004). University of Central Florida, USA. Patent # CA2491639.
A plastid transformation vector for a stably transforming a plastid genome, comprising, as operably-linked components, a first flanking sequence, a DNA sequence coding for synthetic insulin-like growth factor-1 (IGF-1s) (seek ID NO. 1) or a substantially homologous DNA sequence of IGF-1s, which is capabl e of expression in the plastid genome, and a second flanking sequence.
EXPRESSION OF HUMAN INTERFERON IN TRANSGENIC CHLOROPLASTS, H Daniell (2004). University of Central Florida, USA. Patent # WO2004005467.
A plastid transformation vector for a stably transforming a plastid genome is provided. The vector includes, as operably-linked components, a first flanking sequence, a DNA sequence coding for a therapeutic human IFN, which is capable of expression in the plastid and a second flanking sequence. The invention also provides isolated and purified IFN, wherein the IFN is configured in a monomeric or multimeric form and is a structural equivalent to orally administered human IFN. Also provided are methods for variable-expressing biopharmaceutical proteins in plants suitable for mammal consumption. The method includes integrating a plastid transformation vector into a plastid genome of a plant cell; growing the plant cell to express a biopharmaceutical protein, such as therapeutic human interferon IFN. Also disclosed are plants transformed with the aforementioned vectors, and the progeny thereof. Also, disclosed is the IFN, which is IFNalpha2b.
EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES, H Daniell (2003). Florida, USA. Patent # WO03057834.
Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilises antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against Bacillus anthracis, as well as Yersina pestis. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants.
PLASTID TRANSFORMATION VECTORS FOR EXPRESSING HUMAN PROTEINS IN PLANTS, H Daniell (2003). Universities of Auburn & Central Florida, USA. Patent # EP1274846.
PRODUCTION OF ANTIBODIES IN TRANSGENIC PLASTIDS, H Daniell & K Wycoff (2001). Universities of Auburn & Central Florida, USA. Patent # WO0164929.
This invention provides compositions and methods for the transformation of plastids of plant cells with multiple genes, and proper association or assembly of multimeric proteins that are heterologous to the plastids of plant cells. A plasmid construct encoding all of the individual polypeptide components of the multimeric protein is provided. Stable integration of the heterologous coding sequences into the plastid genome of the target plant is accomplished through homologous recombination. The present invention achieves assembly of immunoglobulin heavy and light chains, with covalent bonding between the chains, into immunologically active immunoglobulins in the chloroplast.
PHARMACEUTICAL PROTEINS, HUMAN THERAPEUTICS, HUMAN SERUM ALBUMIN, INSULIN, NATIVE CHOLERA TOXIC B SUBMITTED ON TRANSGENICS PLASTIDS, H Daniell (2001). Universities of Auburn & Central Florida, USA. Patent # WO0172959.
Transgenic chloroplast technology could provide a viable solution to the production of Insulin-like Growth Factor I (IGF-I), Human Serum Albumin (HAS), or interferons (IFN) because of hyper-expression capabilities, ability to fold and process eukaryotic proteins with disulfide bridges (thereby eliminating the need for expensive post-purification processing). Tobacco is an ideal choice because of its large biomass, ease of scale-up (million seeds per plant), genetic manipulation and impending need to explore alternate uses for this hazardous crop. Therefore, all three human proteins will be expressed as follows: a) develop recombinant DNA vectors for enhanced expression via tobacco chloroplast genomes; b) generate transgenic plants; c) characterise transgenic expression of proteins or fusion proteins using molecular and biochemical methods; d) large scale purification of therapeutic proteins from transgenic tobacco and comparison of current purification / processing methods in E.coli or yeast; e) Characterisation and comparison of therapeutic proteins (yield, purity, functionality) produced in yeast or E.coli with transgenic tobacco; f) animal testing and pre-clinical trials for effectiveness of the therapeutic proteins.
BIOSAFETY WEB PAGES
Home Page
Introduction to Biosafety
Databases
General
Agricultural
Bibliographic
Environmental
Glossaries
Health (Human & Animal)
Molecular
Patents
Genetic Elements
Herbicide Tolerance
Industrial Products
Pest Resistance
Phytoremediation
Production Systems
Quality Traits
Species/Family-specific procedures
Stress Tolerance
Therapeutic Protein Production
Research
Treaties/Regulations
Biosafety in Member States
Library

News

In House Publications
Training
ICGEB Biosafety Unit
Padriciano, 99
34149 Trieste, Italy
Tel.: +39-040-3757320
Fax: +39-040-226555
Email: biosafe@icgeb.org